Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2361]
News [4942]
Articles [204]
Editorials [8]
Conferences [138]
elearning [14]
Developments in clinical trials and health information technology that will...
Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA
Developments in clinical trials and health information technology that will improve targeted therapies for patients ( Dr Clifford Hudis, Memorial Sloan Kettering Cancer Center, New York, USA )
1 Jun 2015
Obinutuzumab doubles remission duration in patients with relapsed, indolent non...
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )
31 May 2015
ASCO 2015: Latest developments in prostate cancer treatment
Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi
ASCO 2015: Latest developments in prostate cancer treatment ( Prof Cora Sternberg, Prof Noel Clarke, Prof Eleni Efstathiou, Prof Karim Fizazi )
31 May 2015
New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin...
Dr Merry-Jennifer Markham - University of Florida, Florida, USA
New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis ( Dr Merry-Jennifer Markham - University of Florida, Florida, USA )
30 May 2015
Novel JAK inhibitor pacritinib proving effective for easing symptoms of...
Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA
Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )
30 May 2015
Novel JAK inhibitor pacritinib proves effective for easing symptoms of...
Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA
Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis ( Dr Ruben Mesa - Mayo Clinic Cancer Center, Scottsdale, USA )
30 May 2015
New ibrutinib combination regimen shows substantial benefits in relapsed...
Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA
New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia ( Prof Asher Chanan-Khan - Mayo Clinic, Jacksonville, USA )
30 May 2015
Obinutuzumab doubles remission duration in patients with relapsed, indolent non...
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada
Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma ( Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada )
30 May 2015
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse...
Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA
Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction ( Dr Lynn Schuchter - University of Pennsylvania, Philadelphia, USA )
29 May 2015
Pembrolizumab for head and neck cancer
Dr Tanguy Seiwert - University of Chicago, Chicago, USA
Pembrolizumab for head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )
29 May 2015
Pembrolizumab shows promising activity against head and neck cancer
Dr Tanguy Seiwert - University of Chicago, Chicago, USA
Pembrolizumab shows promising activity against head and neck cancer ( Dr Tanguy Seiwert - University of Chicago, Chicago, USA )
29 May 2015
Latest developments in prostate cancer
Prof Peter Mulders, Prof Axel S. Merseburger, Prof Pablo Maroto, Prof Peter...
Latest developments in prostate cancer ( Prof Peter Mulders, Prof Axel S. Merseburger, Prof Pablo Maroto, Prof Peter Iversen )
20 May 2015

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation